Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 1018

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 1018
---
 after the date hereof which results in gross proceeds to Parent in an amount no less than Twenty Million Dollars ($20,000,000);”

“(u) “Delayed Net Working Capital Amount” means, if the Closing Net Working Capital results in a deficit (e.g., the Closing Net Working Capital is less than the Targeted Net Working Capital) and that deficit is greater than Six Million Dollars ($6,000,000), the difference between the Closing Net Working Capital and Six Million Dollars ($6,000,000);”

“(gg) “Loaned Amount” means all principal and interest outstanding under any loan between Parent and its Affiliates, on the one hand, and the Company and its Affiliates, on the other hand, consisting of (i) $250,000 that was previously advanced by Parent to Company, (ii) $250,000 to be advanced by Parent to the Company on or before May 15, 2025, and (iii) $250,000 to be advanced by Parent to Company on or before June 3, 2025 (with the advance in foregoing clause (iii) being contingent upon Parent’s receipt of (A) proceeds from the Concurrent Investment or (B) proceeds from Parent stockholder warrant exercise payments due on May 30, 2025), in each case, for any expenses incurred by the Company in the ordinary course of business or expenses incurred in connection with the Program Assets and approved by Parent, and such amount shall be paid by Parent to the Company no later than five (5) Business Days after the request is made (and invoice or proof of expense is provided to Parent) as long as no event of default has occurred and is continuing under this Agreement as of the date of such request and so long as the parties hereto are then still working in good faith toward a Closing;”

5. CERTAIN VENDOR MATTERS. The Company hereby agrees that that the Company will at all times prior to and through the Closing take such steps to ensure that, except as otherwise consented to by Parent in writing, the Master Development Services Agreement, dated July 9, 2021 (the “Samsung MDSA”), between the Company and Samsung Biologics Co. Ltd. (“Samsung Biologics”) will remain in effect in accordance with its terms. Parent agrees that it will advance to Company the cost payable to Samsung Biologics for the two June 2025 stability studies proposed by Samsung Biologics (the “Samsung Advance”), and the Company will utilize